Cargando…
LC-ESI-MS/MS reveals the formation of reactive intermediates in brigatinib metabolism: elucidation of bioactivation pathways
Brigatinib (BGB) is a newly approved anaplastic lymphoma kinase (ALK) inhibitor. On April 28, 2017, BGB was approved by the U.S. FDA for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer. The toxicity profile of BGB includes nausea, fatigue, diarrhea, elevate...
Autores principales: | Kadi, Adnan A., Attwa, Mohamed W., Darwish, Hany W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Society of Chemistry
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9077137/ https://www.ncbi.nlm.nih.gov/pubmed/35540908 http://dx.doi.org/10.1039/c7ra10533a |
Ejemplares similares
-
Identification of reactive intermediate formation and bioactivation pathways in Abemaciclib metabolism by LC–MS/MS: in vitro metabolic investigation
por: Kadi, Adnan A., et al.
Publicado: (2019) -
Sapitinib: reactive intermediates and bioactivation pathways characterized by LC-MS/MS
por: Attwa, Mohamed W., et al.
Publicado: (2019) -
Characterization of reactive intermediates formation in dacomitinib metabolism and bioactivation pathways elucidation by LC-MS/MS: in vitro phase I metabolic investigation
por: Attwa, Mohamed W., et al.
Publicado: (2018) -
Identification and characterization of in vivo, in vitro and reactive metabolites of vandetanib using LC–ESI–MS/MS
por: Attwa, Mohamed W., et al.
Publicado: (2018) -
Identification of Iminium Intermediates Generation in the Metabolism of Tepotinib Using LC-MS/MS: In Silico and Practical Approaches to Bioactivation Pathway Elucidation
por: Abdelhameed, Ali S., et al.
Publicado: (2020)